JACC. Heart failure最新文献

{"title":"Patient-Reported Outcomes in Heart Failure","authors":"Gregg C. Fonarow MD , Amber B. Tang MD","doi":"10.1016/j.jchf.2024.10.019","DOIUrl":"10.1016/j.jchf.2024.10.019","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages 293-295"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143179805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can and Should LIVE Be Revived?","authors":"Michael I. Brener MD, MS, Daniel Burkhoff MD, PhD","doi":"10.1016/j.jchf.2025.01.001","DOIUrl":"10.1016/j.jchf.2025.01.001","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages 312-314"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143181334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Full issue PDF","authors":"","doi":"10.1016/S2213-1779(25)00002-2","DOIUrl":"10.1016/S2213-1779(25)00002-2","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages i-ccx"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143180846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy","authors":"Pablo Garcia-Pavia MD, PhD ,&nbsp;Ozlem Bilen MD ,&nbsp;Melissa Burroughs MD ,&nbsp;Juan Pablo Costabel MD ,&nbsp;Edileide de Barros Correia MD ,&nbsp;Anne M. Dybro MD, PhD ,&nbsp;Perry Elliott MBBS, MD ,&nbsp;Neal K. Lakdawala MD ,&nbsp;Amy Mann BA ,&nbsp;Ajith Nair MD ,&nbsp;Michael E. Nassif MD ,&nbsp;Steen H. Poulsen MD ,&nbsp;Patricia Reant MD, PhD ,&nbsp;P. Christian Schulze MD ,&nbsp;Andrew Wang MD ,&nbsp;Indrias Berhane PhD ,&nbsp;Stephen B. Heitner MD ,&nbsp;Daniel L. Jacoby MD ,&nbsp;Stuart Kupfer MD ,&nbsp;Fady I. Malik MD, PhD ,&nbsp;Michael A. Fifer MD","doi":"10.1016/j.jchf.2024.11.011","DOIUrl":"10.1016/j.jchf.2024.11.011","url":null,"abstract":"<div><div>Beta-blockers and nondihydropyridine calcium-channel blockers have been standard-of-care (SOC) medications for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), even though these agents do not directly affect the underlying pathophysiology of the disease. Cardiac myosin inhibitors act by decreasing the number of myosin heads binding to actin, reducing the pathologic hypercontractility of HCM, and have been shown to improve exercise capacity and alleviate symptoms in oHCM when added to SOC medications. Cardiac myosin inhibitors are currently considered as second-line therapy in the absence of head-to-head comparison studies vs SOC medications. The aim of the ongoing phase 3 study MAPLE-HCM (Metoprolol vs Aficamten in Patients With LVOT Obstruction on Exercise Capacity in HCM) is to fill this evidence gap by evaluating aficamten as both first-line therapy for newly diagnosed oHCM and as a monotherapy alternative for patients currently on SOC drugs. The authors describe the rationale, design, and baseline characteristics of patients in this study. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM [MAPLE-HCM]; <span><span>NCT05767346</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages 346-357"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143180875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Mitral TEER in the Management of Moderate Secondary Mitral Regurgitation Among Heart Failure Patients","authors":"Anita W. Asgar MD ,&nbsp;Gilbert H.L. Tang MD ,&nbsp;Jason H. Rogers MD ,&nbsp;Wolfgang Rottbauer MD ,&nbsp;M. Andrew Morse MD ,&nbsp;Paolo Denti MD ,&nbsp;Paul Mahoney MD ,&nbsp;Michael J. Rinaldi MD ,&nbsp;Federico M. Asch MD ,&nbsp;Jose L. Zamorano MD ,&nbsp;Melody Dong PhD ,&nbsp;Rong Huang MS ,&nbsp;Joann Lindenfeld MD ,&nbsp;Francesco Maisano MD ,&nbsp;Ralph Stephan von Bardeleben MD ,&nbsp;Saibal Kar MD ,&nbsp;Evelio Rodriguez MD","doi":"10.1016/j.jchf.2024.08.001","DOIUrl":"10.1016/j.jchf.2024.08.001","url":null,"abstract":"<div><h3>Background</h3><div>Moderate secondary mitral regurgitation (SMR) represents a subgroup of heart failure (HF) patients with treatment restricted to medical therapy. Outcomes in patients with moderate SMR treated with mitral transcatheter edge-to-edge repair (M-TEER) are less well known.</div></div><div><h3>Objectives</h3><div>The aim of this study was to assess the safety and effectiveness of M-TEER in subjects with moderate SMR using the EXPANDed studies.</div></div><div><h3>Methods</h3><div>One-year outcomes in subjects from the EXPANDed studies (EXPAND [A Contemporary, Prospective Study Evaluating Real-world Experience of Performance and Safety for the Next Generation of MitraClip Devices] and EXPAND G4 [A Post-Market Study Assessment of the Safety and Performance of the MitraClip G4 System] MitraClip studies) with baseline moderate SMR (2+), per echocardiographic core laboratory (ECL) assessment, were compared with subjects with baseline severe SMR (≥3+).</div></div><div><h3>Results</h3><div>There were 335 subjects with moderate SMR and 525 with severe SMR at baseline per ECL review. Baseline characteristics were similar between the 2 subgroups. After treatment with M-TEER, significant MR reduction was achieved in both groups. Significant left ventricular (LV) reverse remodeling was observed through 1 year, with a &gt;20 mL decrease in LV end-diastolic and end-systolic volumes on average in the moderate SMR group. Significant 1-year improvements in NYHA functional class (&gt;78% NYHA functional class I or II) and quality of life (&gt;20 points on the Kansas City Cardiomyopathy Questionnaire–Overall Summary) were observed in subjects with moderate SMR. Similarly, low rates of major adverse events, all-cause mortality, and HF hospitalizations were observed between the 2 subgroups through 1 year.</div></div><div><h3>Conclusions</h3><div>In the EXPANDed studies, subjects with moderate SMR treated with M-TEER had improvements similar to subjects with severe SMR in quality of life and positive LV remodeling at 1 year. Future studies are needed to evaluate if M-TEER would be beneficial for HF patients with moderate SMR.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages 213-225"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142269281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Heart Failure Outcomes and Medical Therapy Use in a Virtually Managed Hospital at Home Setting","authors":"Trejeeve Martyn MD, MSc ,&nbsp;Harsh Patolia MD ,&nbsp;Nicholas Platek DO ,&nbsp;Ryan Tang MD ,&nbsp;Nancy M. Albert PhD ,&nbsp;Danielle Crow MSN ,&nbsp;Amanda R. Vest MBBS, MPH ,&nbsp;Samir Kapadia MD ,&nbsp;Raed Dweik MD ,&nbsp;Lars G. Svensson MD, PhD ,&nbsp;Jerry D. Estep MD ,&nbsp;Conor P. Delaney MD, PhD ,&nbsp;Richard D. Rothman MD ,&nbsp;Jessica Hohman MD, MSc, MSc","doi":"10.1016/j.jchf.2024.10.007","DOIUrl":"10.1016/j.jchf.2024.10.007","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages 381-385"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Designing Effective Trials for Acute Decompensated Heart Failure","authors":"Johannes Grand MD, PhD, MPH ,&nbsp;Tor Biering-Sørensen MD, MSc, MPH, PhD ,&nbsp;John R. Teerlink MD","doi":"10.1016/j.jchf.2024.11.010","DOIUrl":"10.1016/j.jchf.2024.11.010","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages 253-259"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143179807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospitalized Advanced Heart Failure With Preserved vs Reduced Left Ventricular Ejection Fraction","authors":"Vasiliki Bistola MD, PhD ,&nbsp;Dimitrios Farmakis MD, PhD ,&nbsp;Jasper Tromp MD, PhD ,&nbsp;Wan Ting Tay MApp STAT ,&nbsp;Wouter Ouwerkerk PhD ,&nbsp;Christiane E. Angermann MD ,&nbsp;John G.F. Cleland MD ,&nbsp;Ulf Dahlström MD, PhD ,&nbsp;Kenneth Dickstein MD, PhD ,&nbsp;Georg Ertl MD ,&nbsp;Mahmoud Hassanein MD ,&nbsp;Sotiria Liori MD ,&nbsp;Petros Nikolopoulos MD ,&nbsp;Sergio V. Perrone MD ,&nbsp;Mathieu Ghadanfar MD ,&nbsp;Anja Schweizer PhD ,&nbsp;Achim Obergfell MD ,&nbsp;Sean P. Collins MD ,&nbsp;Carolyn S.P. Lam MBBS, PhD ,&nbsp;Gerasimos Filippatos MD","doi":"10.1016/j.jchf.2024.09.009","DOIUrl":"10.1016/j.jchf.2024.09.009","url":null,"abstract":"<div><h3>Background</h3><div>Outcomes of hospitalized patients with heart failure (HF) and characteristics of advanced HF stage may vary across left ventricular ejection fraction (LVEF) and world regions.</div></div><div><h3>Objectives</h3><div>This study sought to analyze characteristics of hospitalized advanced HF patients across LVEF spectrum, world regions, and country income.</div></div><div><h3>Methods</h3><div>Among 18,553 hospitalized patients with acute HF (7,902 new-onset HF and 10,651 decompensated chronic HF) enrolled in the global registry REPORT-HF (International Registry to Assess Medical Practice With Longitudinal Observation for Treatment of Heart Failure), the authors analyzed characteristics and outcomes of patients with advanced HF, defined as previously diagnosed HF; severe symptoms before current admission (NYHA functional class III/IV); and ≥1 HF-related hospitalization in the preceding 12 months, excluding the current. Differences among hospitalized advanced HF subgroups stratified by LVEF, world region, and country income were examined.</div></div><div><h3>Results</h3><div>Among 6,999 patients with decompensated chronic HF and available previous NYHA functional class and HF hospitalization status, 3,397 (48.5%; 18.3% of the total population) had advanced HF. Of these, 44.5% had severely reduced (≤30%), 34.9% mildly/moderately reduced (31%-49%), and 20.7% preserved (≥50%) LVEF. Patients from Eastern Europe had the lowest 1-year mortality (23%), whereas those from Southeast Asia had the highest (37%). Patients from lower-middle-income countries were younger, with shorter HF duration and lower comorbidity prevalence, received fewer beta-blockers and HF-devices, and had higher 1-year mortality (34%) than upper-middle-income (26%) or high-income countries (27%; <em>P</em> = 0.018). Adjusted 1-year mortality risk did not differ among LVEF subgroups (all <em>P</em> &gt; 0.05), nor did 1-year HF hospitalization rate (<em>P</em> = 0.56).</div></div><div><h3>Conclusions</h3><div>Hospitalized patients with advanced HF and preserved LVEF had similarly adverse outcomes as those with reduced LVEF. Patients from lower-middle-income countries had less implementation of HF therapies and higher 1-year mortality.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages 229-247"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142620685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter Left Ventricular Reconstruction in Heart Failure Patients With Prior Anterior Myocardial Infarction","authors":"Jerry D. Estep MD ,&nbsp;Ori Ben-Yehuda MD ,&nbsp;Andrew S. Wechsler MD ,&nbsp;Rishi Puri MD, PhD ,&nbsp;Andrew C. Kao MD ,&nbsp;Jessica K. Heimes DO ,&nbsp;Michael P. Pfeiffer MD ,&nbsp;John P. Boehmer MD ,&nbsp;Vlasis Ninios MD ,&nbsp;Azfar Zaman MD ,&nbsp;Gregg W. Stone MD","doi":"10.1016/j.jchf.2024.09.023","DOIUrl":"10.1016/j.jchf.2024.09.023","url":null,"abstract":"<div><h3>Background</h3><div>Left ventricular (LV) dilatation and extensive scar portend a poor prognosis in heart failure (HF). The Revivent TC system (BioVentrix Inc) is used either during a hybrid transcatheter-surgical or a surgical-only procedure to exclude transmural scar and reduce LV dimensions.</div></div><div><h3>Objectives</h3><div>The purpose of this study was to examine the safety and efficacy of the Revivent TC® anchor system in patients with HF.</div></div><div><h3>Methods</h3><div>The authors conducted a prospective, multicenter, nonrandomized (2:1 device vs control) trial in patients with NYHA functional class III-IV symptoms, LV ejection fraction ≤45%, LV end-systolic volume index ≥50 mL/m², and transmural anterior LV scar. Patients with inadequate scar or previous sternotomy served as the control group. The primary safety endpoint was the composite of major adverse events in the device arm compared with a performance goal of 40.5%. The primary effectiveness endpoint was the hierarchical composite of cardiovascular mortality, HF hospitalization, change in 6-minute walk test, change in Minnesota Living With Heart Failure questionnaire score, and change in NYHA functional classification assessed at 12 months as the win ratio in the device group compared with the control group.</div></div><div><h3>Results</h3><div>In total, 126 patients (84 device; 42 control) were enrolled at 28 sites. Mean LV ejection fraction was 29.6% ± 7.2%, and mean LV end-systolic volume index was 93.9 ± 35.5 mm. The primary 30-day safety performance goal endpoint was met (major adverse events 15 of 84 [17.9%]; 1-sided 97.5% upper confidence limit 27.7%; <em>P &lt;</em> 0.0001). There was no significant difference in the primary 12-month hierarchical composite efficacy endpoint (win ratio 1.13; <em>P =</em> 0.32). In post hoc analysis, the surgical only approach (23 treated patients) had more favorable outcomes than the hybrid approach (60 treated patients).</div></div><div><h3>Conclusions</h3><div>The Revivent TC® system safely reduced LV dimensions in HF patients caused by extensive anterior scar but did not improve clinical effectiveness outcomes at 1 year. A randomized trial is warranted to further define the risks and benefits of the surgical only approach. (BioVentrix Revivent TC™ System Clinical Study; <span><span>NCT02931240</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages 296-308"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142965053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"We Need Simpler and More Integrated Guidelines in Cardio-Kidney-Metabolic Diseases","authors":"João Pedro Ferreira MD, PhD ,&nbsp;Faiez Zannad MD, PhD","doi":"10.1016/j.jchf.2024.10.025","DOIUrl":"10.1016/j.jchf.2024.10.025","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 2","pages":"Pages 371-374"},"PeriodicalIF":10.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142965054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}